CompletedNCT00139594
Long-term safety of licarbazepine after treatment for mania
About this title
Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
Read the official source — NCT00139594Researchers studied licarbazepine, tracking side effects to assess safety and tolerability in people with bipolarity type I during a manic episode.
Medication studyAges 18–70Multiple countries
Understand this study
What did researchers investigate?
Researchers studied licarbazepine, tracking side effects to assess safety and tolerability in people with bipolarity type I during a manic episode.
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- La Palma and 43 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 181
- Sponsor
- Novartis
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, Canada, Austria, ...
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00139594
- Official title
Show the full official title
A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
La Palma, United States · Kansas City, United States · Shreveport, United States
43 more locations
- Somerville, United States
- Farmington Hills, United States
- Staten Island, United States
- Madison, United States
- Bellaire, United States
- Dallas, United States
- Verdun, United States
- Bellevue, United States
- Kirkland, United States
- West Allis, United States
- Vienna, Austria
- Greater Sudbury, Canada
- Kelowna, Canada
- London, Canada
- Montreal, Canada
- Vancouver, Canada
- Bogotá, Colombia
- Medellín, Colombia
- Pareira, Colombia
- Brno, Czechia
- Hradec Králové, Czechia
- Prague, Czechia
- Berlin, Germany
- Bochum, Germany
- Dresden, Germany
- Ingolstadt, Germany
- Mannheim, Germany
- Würzburg, Germany
- Guatemala City, Guatemala
- Lima, Peru
- Moscow, Russia
- Yaroslavl, Russia
- Bojnice, Slovakia
- Michalovce, Slovakia
- Durban, South Africa
- Dnipro, Ukraine
- Kiev, Ukraine
- Luhansk, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Caracas, Venezuela
- Czechia
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied licarbazepine, tracking side effects to assess safety and tolerability in people with bipolarity type I during a manic episode.
Who is behind this study?
The study sponsor is Novartis.
Did this study involve medication?
Yes. The study involved medication, including licarbazepine.
Who was this study for?
Listed age limits: 18 years to 70 years.
